| Literature DB >> 34436298 |
Gennaro Riccio1, Genoveffa Nuzzo2, Gianluca Zazo3, Daniela Coppola1, Giuseppina Senese2, Lucia Romano2, Maria Costantini1,4, Nadia Ruocco1, Marco Bertolino5, Angelo Fontana2,6, Adrianna Ianora1, Cinzia Verde1,4, Daniela Giordano1,4, Chiara Lauritano1.
Abstract
Sponges are known to produce a series of compounds with bioactivities useful for human health. This study was conducted on four sponges collected in the framework of the XXXIV Italian National Antarctic Research Program (PNRA) in November-December 2018, i.e., Mycale (Oxymycale) acerata, Haliclona (Rhizoniera) dancoi, Hemimycale topsenti, and Hemigellius pilosus. Sponge extracts were fractioned and tested against hepatocellular carcinoma (HepG2), lung carcinoma (A549), and melanoma cells (A2058), in order to screen for antiproliferative or cytotoxic activity. Two different chemical classes of compounds, belonging to mycalols and suberitenones, were identified in the active fractions. Mycalols were the most active compounds, and their mechanism of action was also investigated at the gene and protein levels in HepG2 cells. Of the differentially expressed genes, ULK1 and GALNT5 were the most down-regulated genes, while MAPK8 was one of the most up-regulated genes. These genes were previously associated with ferroptosis, a programmed cell death triggered by iron-dependent lipid peroxidation, confirmed at the protein level by the down-regulation of GPX4, a key regulator of ferroptosis, and the up-regulation of NCOA4, involved in iron homeostasis. These data suggest, for the first time, that mycalols act by triggering ferroptosis in HepG2 cells.Entities:
Keywords: Antarctica; drug discovery; marine biotechnology; mycalols; sponges
Mesh:
Substances:
Year: 2021 PMID: 34436298 PMCID: PMC8400861 DOI: 10.3390/md19080459
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Work pipeline reporting the various experimental steps, the chemical structures of suberitenone A (1) and B (2) and mycalols, and the main results on the mechanism of action of mycalols, which were identified as the most active compounds in the current study.
Collected species and relative sample IDs and MNA codes.
| Species Name | Abbreviation | Sample IDs | MNA Code |
|---|---|---|---|
|
| D4 | 13266 | |
|
| C6 | 13265 | |
|
| B4 | 13264 | |
|
| C7 | 13860 |
Figure 2Molecular structure of suberitenones A (1) and B (2), and mycalols (3–9).
Figure 3Cell viability assay. The figure shows the anti-proliferative effects of mycalols (red line) on A549 (a), A2058 (b), HepG2 (c), and MRC5 (d) cell lines, at increasing concentrations (0.05, 0.10, 0.19, 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100 μM). Control cells were incubated with complete cell medium and DMSO. Results are expressed as percent survival after 72 h exposure.
IC50 values of mycalols, suberitenone A and B bioactivity against A549, A2058, HepG2, and MRC5 cell lines. Values are expressed in μM.
| Compounds | A549 | A2058 | HepG2 | MRC5 |
|---|---|---|---|---|
| Mycalols | 10.1 | 15.3 | 9.0 | 21.3 |
| Suberitenones A ( | 28.5 | 10.2 | 17.6 | 7.4 |
| Suberitenones B ( | 80.7 | 14.6 | 19.2 | 8.5 |
Transcriptional modulation of a subset of genes involved in human cell death signaling pathways in mycalols-treated HepG2 cells. Gene transcription is considered unaffected by compound treatment if fold regulation is in the range ± 2.0.
| Unigene | RefSeq | Symbol | Description | Fold | SD |
|---|---|---|---|---|---|
|
| |||||
| Hs.47061 | NM_003565 | ULK1 | Unc-51-like kinase 1 ( | −12.03 | 0.025 |
| Hs.269027 | NM_014568 | GALNT5 | UDP- | −10.71 | 0.001 |
| Hs.2490 | NM_033292 | CASP1 | Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) | −6.85 | 0.005 |
| Hs.484111 | NM_002546 | TNFRSF11 | Tumor necrosis factor receptor superfamily, member 11b | −5.57 | 0.001 |
| Hs.81791 | NM_014592 | KCNIP1 | Kv channel interacting protein 1 | −2.57 | 0.001 |
| Hs.160562 | NM_000618 | IGF1 | Insulin-like growth factor 1 (somatomedin C) | −2.41 | 0.002 |
| Hs.552567 | NM_001160 | APAF1 | Apoptotic peptidase activating factor 1 | −2.03 | 0.026 |
|
| |||||
| Hs.513667 | NM_003946 | NOL3 | Nucleolar protein 3 (apoptosis repressor with CARD domain) | 7.40 | 0.029 |
| Hs.227817 | NM_004049 | BCL2A1 | BCL2-related protein A1 | 5.14 | 0.002 |
| Hs.587290 | NM_003900 | SQSTM1 | Sequestosome 1 | 4.75 | 1.256 |
| Hs.442337 | NM_176823 | S100A7A | S100 calcium binding protein A7A | 4.15 | 0.001 |
| Hs.553833 | NM_001004467 | OR10J3 | Olfactory receptor, family 10, subfamily J, member 3 | 4.05 | 0.001 |
| Hs.202676 | NM_014258 | SYCP2 | Synaptonemal complex protein 2 | 3.74 | 0.001 |
| Hs.138211 | NM_002750 | MAPK8 | Mitogen-activated protein kinase 8 | 3.71 | 0.132 |
| Hs.519680 | NM_001145805 | IRGM | Immunity-related GTPase family, M | 3.19 | 0.001 |
| Hs.643440 | NM_002361 | MAG | Myelin associated glycoprotein | 3.17 | 0.006 |
| Hs.181301 | NM_004079 | CTSS | Cathepsin S | 2.97 | 0.004 |
| Hs.32949 | NM_005218 | DEFB1 | Defensin, beta 1 | 2.74 | 0.005 |
| Hs.29169 | NM_024610 | HSPBAP1 | HSPB (heat shock 27kDa) associated protein 1 | 2.28 | 0.03 |
Figure 4Effects of the mycalol mixture on ferroptosis-related proteins glutathione peroxidase 4 (GPX4) and nuclear receptor coactivator 4 (NCOA4). Western blotting analyses with anti-GPX4 (a) or anti-NCOA4 (b) antibody of the extracts from HepG2 treated with the DMSO alone (control) or in the presence of mycalols. The intensity of the bands of GPX4 (c) and NCOA4 (d) were normalized, respectively, with β-tubulin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH), used as standard proteins, and are reported as relative to GPX4 and NCOA4 levels (* p < 0.05; ** p < 0.01).